TABLE 1.
Targeted genes | Primer sequences |
miR-448 | F: 5′-TTATTGCGATGTGTTCCTTATG-3′ |
R: 5′-ATGCATGCCACGGGCATATACACT-3′ | |
miR-133b | F: 5′-GCGCTTTGGTCCCCTTC-3′ |
R: 5′-CAGTGCAGGGTCCGAGGT-3′ | |
PRDM16 | F: 5′-CCACCAGCGAGGACTTCAC-3′ |
R: 5′-GGAGGACTCTCGTAGCTCGAA-3′ | |
TGF-β | F: 5′-CCACCTGCAAGACCATCGAC-3′ |
R: 5′-CTGGCGAGCCTTAGTTTGGAC-3′ | |
Smad2 | F: 5′-AAGCCATCACCACTCAGAATTG-3′ |
R: 5′-CACTGATCTACCGTATTTGCTGT-3′ | |
Smad3 | F: 5′-AGGGGCTCCCTCACGTTATC-3′ |
R: 5′-CATGGCCCGTAATTCATGGTG-3′ | |
U6 | F: 5′-CTCGCTTCGGCAGCACA-3′ |
R: 5′-AACGCTTCACGAATTTGCGT-3′ | |
GAPDH | F: 5′-GGAGCGAGATCCCTCCAAAAT-3′ |
R: 5′-GGCTGTTGTCATACTTCTCATGG-3′ |
F, forward; R, reverse; miR-448, microRNA-448; miR-133b, microRNA-133b; PRDM16, PR domain containing 16; TGF-β, transforming growth factor β; Smad2, SMAD family member 2; Smad3, SMAD family member 3; RT-qPCR, reverse transcription quantitative polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.